Raju S Kucherlapati

US Patent:

6514752, Feb 4, 2003

Filed:

May 18, 1995

Appl. No.:

08/443613

Inventors:

Raju Kucherlapati - Darien CT
Beverly H. Koller - Carrboro NC
Oliver Smithies - Chapel Hill NC
Robert B. Dubridge - Belmont CA
Gary Greenburg - San Carlos CA
Daniel J. Capon - Hillsborough CA
Steven R. Williams - San Francisco CA
Mariona Lourdes Arbones De Rafael - Barcelona, ES

Assignee:

Cell Genesys, Inc. - Foster City CA

International Classification:

C12N 1574

US Classification:

4353201, 435325, 435455, 536 231, 800 13

Abstract:

Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the -microglobulin gene is inactivated for reducing or eliminating the expression of functional Class I MHC antigens. The resulting cells may be used as universal donor cells. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.

US Patent:

6657103, Dec 2, 2003

Filed:

Sep 4, 1997

Appl. No.:

08/923138

Inventors:

Raju Kucherlapati - Darien CT
Aya Jakobovits - Menlo Park CA
Sue Klapholz - Stanford CA
Daniel G. Brenner - San Mateo CA
Daniel J. Capon - Hillsborough CA

Assignee:

Abgenix, Inc. - Fremont CA

International Classification:

C12P 2100

US Classification:

800 6, 800 4, 800 18, 4353201

Abstract:

Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.

US Patent:

6673986, Jan 6, 2004

Filed:

Mar 15, 1993

Appl. No.:

08/031801

Inventors:

Raju Kucherlapati - Darien CT
Aya Jakobovits - Menlo Park CA
Sue Klapholz - Stanford CA
Daniel G. Brenner - Redwood City CA
Daniel J. Capon - Hillsborough CA

Assignee:

Abgenix, Inc. - Fremont CA

International Classification:

A01K 67033

US Classification:

800 18, 800 13, 435325, 435455

Abstract:

The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.

US Patent:

6713610, Mar 30, 2004

Filed:

Jul 11, 2000

Appl. No.:

09/614092

Inventors:

Raju Kucherlapati - Darien CT 06820
Aya Jakobovits - Menlo Park CA 94025
Daniel G. Brenner - Redwood City CA 94601
Daniel J. Capon - Hillsborough CA 94010
Sue Klapholz - Stanford CA 94305

International Classification:

A61K 39395

US Classification:

53038823, 5303871, 5303881, 53038815, 4241301, 4241321, 4241411, 4241471, 4241451

Abstract:

Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.

US Patent:

6794147, Sep 21, 2004

Filed:

Nov 21, 2001

Appl. No.:

09/991099

Inventors:

Jeffrey W. Pollard - New York NY
Winfried Edelmann - Bronx NY
Paula E. Cohen - Bronx NY
Burkhard Kneitz - Wurzburg, DE
Panos Stevis - Glenmoore PA
Raju S. Kucherlapati - Boston MA

Assignee:

Wyeth - Madison NJ
Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

G01N 3353

US Classification:

435 71, 435 4, 435 6

Abstract:

An animal, e. g. , transgenic mouse, in which the MSH4 gene is misexpressed. The animal is useful for screening treatments for a number of conditions. Methods for identifying contraceptive agents are also described.

US Patent:

7064244, Jun 20, 2006

Filed:

Feb 19, 2002

Appl. No.:

10/078958

Inventors:

Aya Jakobovits - Menlo Park CA, US
Raju Kucherlapati - Darien CT, US
Susan Klapholz - Stanford CA, US
Michael J Mendez - El Granada CA, US
Larry Green - San Francisco CA, US

Assignee:

Abgenix, Inc. - Fremont CA

International Classification:

A01K 67/027
A01K 67/033
C12P 21/00

US Classification:

800 18, 800 13, 800 6

Abstract:

The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (Vand Vκ) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.

US Patent:

7820877, Oct 26, 2010

Filed:

Oct 14, 2005

Appl. No.:

11/250805

Inventors:

Aya Jakobovits - Menlo Park CA, US
Raju Kucherlapati - Darien CT, US
Sue Klapholz - Stanford CA, US
Michael J. Mendez - El Granada CA, US
Larry Green - San Francisco CA, US

Assignee:

Amgen Fremont Inc. - Wilmington DE

International Classification:

A01K 67/027
C12P 21/00

US Classification:

800 18, 800 6, 800 21

Abstract:

The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (Vand Vκ) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.

US Patent:

20030229905, Dec 11, 2003

Filed:

Apr 21, 2003

Appl. No.:

10/421011

Inventors:

Raju Kucherlapati - Darien CT, US
Aya Jakobovits - Menlo Park CA, US
Sue Klapholz - Stanford CA, US
Daniel Brenner - Redwood City CA, US
Daniel Capon - Hillsborough CA, US

Assignee:

Abqenix, Inc.

International Classification:

C12P021/04

US Classification:

800/006000, 435/070210

Abstract:

The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.